BioPharmX Corporation Expands Management Team to S
Post# of 223
Posted On: 09/29/2015 9:55:07 AM
BioPharmX Corporation Expands Management Team to Support Growth and Market Expansion
MENLO PARK, Calif., Sept. 29, 2015 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on women's health and dermatology, today announced the appointment of two executives to strengthen the company's operations and marketing efforts.
Nathan Harris was named senior vice president of operations and Elizabeth Shoemaker joins as the company's senior vice president of marketing.
Harris will spearhead BioPharmX Corporation's multi-faceted operational initiatives in the company's rapidly expanding production of its commercially available product Violet® iodine, as well as establish operational infrastructure for its upcoming drug candidate BPX-01 for the treatment of acne.
Harris brings nearly 20 years of biopharma industry experience to BioPharmX. Most recently as chief operating officer of Amunix, a privately-held biotech company based in Mountain View, Calif., Harris focused on the execution of company strategy and managed all business and operational aspects. He previously worked as a scientist and operations executive at several companies including Molecular Sensing, Inc., Moredun Research Institute, and Vermillion, Inc. (formerly Ciphergen BioSystems).
As senior vice president of marketing, Shoemaker is responsible for setting company-wide consumer and physician marketing strategy at BioPharmX, encompassing consumer insights, target segmentation, brand strategies and omni-channel communication across all online and offline paid, earned and owned media. Before BioPharmX, her marketing expertise contributed to brand and business growth for global Fortune 100 companies, including Safeway, Microsoft, Abbott Nutrition, Coca-Cola, McDonald's, P&G, Chevron/Texaco, and United/American/Alaska airlines.
"Nathan and Elizabeth will deepen our managerial strength, enhancing the skills we need to keep pace with our company's growth plans," said BioPharmX CEO, Jim Pekarsky. "Their skills and backgrounds will speed our ability to scale BioPharmX in terms of operational effectiveness, public perception and increased revenues."
MENLO PARK, Calif., Sept. 29, 2015 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on women's health and dermatology, today announced the appointment of two executives to strengthen the company's operations and marketing efforts.
Nathan Harris was named senior vice president of operations and Elizabeth Shoemaker joins as the company's senior vice president of marketing.
Harris will spearhead BioPharmX Corporation's multi-faceted operational initiatives in the company's rapidly expanding production of its commercially available product Violet® iodine, as well as establish operational infrastructure for its upcoming drug candidate BPX-01 for the treatment of acne.
Harris brings nearly 20 years of biopharma industry experience to BioPharmX. Most recently as chief operating officer of Amunix, a privately-held biotech company based in Mountain View, Calif., Harris focused on the execution of company strategy and managed all business and operational aspects. He previously worked as a scientist and operations executive at several companies including Molecular Sensing, Inc., Moredun Research Institute, and Vermillion, Inc. (formerly Ciphergen BioSystems).
As senior vice president of marketing, Shoemaker is responsible for setting company-wide consumer and physician marketing strategy at BioPharmX, encompassing consumer insights, target segmentation, brand strategies and omni-channel communication across all online and offline paid, earned and owned media. Before BioPharmX, her marketing expertise contributed to brand and business growth for global Fortune 100 companies, including Safeway, Microsoft, Abbott Nutrition, Coca-Cola, McDonald's, P&G, Chevron/Texaco, and United/American/Alaska airlines.
"Nathan and Elizabeth will deepen our managerial strength, enhancing the skills we need to keep pace with our company's growth plans," said BioPharmX CEO, Jim Pekarsky. "Their skills and backgrounds will speed our ability to scale BioPharmX in terms of operational effectiveness, public perception and increased revenues."
(0)
(0)